REGISTER
Dr Nicolas Girard at ASCO 2025 -- MedJ interview
The main question is how Dr Nicolas Girard at ASCO 2025 -- MedJ interview should now be interpreted. It distills the central data on ASCO, EORTC-ETOP, NIVOTHYM into a clear account of the article's most important conclusions.

MedJ takes you straight to ASCO 2025.

Professor Nicolas Girard from Institut Curie in Paris, France, rewrote the history of thymic carcinoma treatment with the world's first EORTC-ETOP NIVOTHYM Phase III study, overcoming the challenge of immunotherapy resistance!

0
0
Loading